Publication | Closed Access

Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial

UrologyOncologyGenitourinary CancerMedicineClinical TrialsPlacebo-controlled TrialPharmacotherapyCancer TreatmentProstatic DiseasePharmacologyPhase 3Elm-pc 4